Background and Purpose-Conventional analysis of vascular prevention trials assigns equal weight to disparate vascular events in a composite end point at variance with the public's perception of their differential impact on health outcome. This study sought to apply the disability-adjusted life-year (DALY) metric to differential weighting individual vascular end points in trial analyses. Methods-DALY values for the most common major end points in vascular prevention trials (nonfatal myocardial infarction, nonfatal stroke, and vascular death), were derived by using World Health Organization Global Burden of Disease Project methodology. The standardized DALYs for each event were applied to recent major primary and secondary vascular prevention trials and to hypothetical model trials. Results-Standardized DALYs lost were 7.63 for nonfatal stroke, 5.14 for nonfatal myocardial infarction, and 11.59 for vascular death. In the published trials analyses, the direction of treatment effects was consistent between DALY and standard event analysis, but the rank order of treatment effect changed for 10 of 18 trials. The DALY analysis also permitted derivation of number-needed-to-treat values to gain 1 DALY: 2.1 for anticoagulation in atrial fibrillation, 2.7 for carotid endarterectomy in symptomatic stenosis, and 4.7 for clopidogrel added to aspirin in acute coronary syndrome. Hypothetical trial analyses demonstrated that the DALY metric more finely discriminates treatment effects. 
D
iseases and their treatment can influence many organs in diverse ways. Consequently, in all medical specialties, composite end points are increasingly used in randomized clinical trials. Composite end points capture the number of patients who have 1 or more of several events of interest. By incorporating a range of important end points in a single metric, composite end points can index the overall impact of therapeutic interventions and reduce sample size requirements. However, composite end points have well-recognized limitations that arise from the common practice of weighting all end point components equally, irrespective of their relative impact on the life of the patient. If positive results are driven by less-salient end points, the trial may give the misleading impression of broad benefit. If treatment exerts differential benefit and harm on different end point components, a treatment may reduce the net number of events but actually worsen global health-related quality of life. Many clinical trialists and statisticians have recognized the desirability of differential weighting of clinical trial end points, but a widely acceptable weighting method has not been advanced.
In vascular disease prevention trials, this tension has given rise to 2 opposing approaches in end point selection: the organ-specific and the multiorgan paradigm. The organspecific approach asserts that end points should focus on the same vascular bed as the presenting event, because recurrent events are likely to cluster in that vascular bed. 1 Including events outside the presenting vascular bed may dilute the measurement of a desired effect on the target organ at greatest risk. 2 A weakness of the organ-specific argument is that, even if less frequent, events outside the initially symptomatic vascular bed are clinically relevant and accumulate as time goes by. 3 In contrast, the multiorgan paradigm uses compos-ite outcomes, such as the first occurrence of nonfatal stroke, transient ischemic attack, nonfatal myocardial infarction (MI), angina, or vascular death, but has generally weighted each of these disparate events equally.
The disability-adjusted life-year (DALY) metric, which the World Health Organization Global Burden of Disease Project (WHO-GBDP) developed to measure the global burden of diseases, 4 is a promising metric to weight components of composite end points in clinical trials. The DALY method converts hundreds of health conditions into a uniform, patient-centered metric of healthy life-years lost by quantifying years lost due to premature mortality and optimum health years lost due to living with disability.
The objective of this study was to develop standardized DALY values for the most common end points assessed in vascular disease prevention trials, that is, nonfatal stroke, nonfatal MI, and vascular death; to apply these values to completed vascular prevention trials to quantify the efficacy of existing prevention treatments; and to compare DALY measures with conventional measures of clinical efficacy.
Methods

Trial Selection and Data Collection
For the analysis, we selected pivotal primary and secondary prevention trials of antiplatelets, statins, antihypertensives, and surgery, including (1) diverse treatment interventions in diverse target populations, (2) recent trials of major clinical importance, and (3) a subset of trials in which tested treatments exerted opposite-direction effects on coronary and cerebrovascular end point events (as these pose special difficulty to traditional end point analysis). Technical inclusion criteria were (1) randomized controlled trial; (2) individual event numbers for nonfatal stroke, nonfatal MI, vascular death, and composite end point (nonfatal stroke, nonfatal MI, and vascular death) separately stated or could be directly estimated from published tables; (3) Ͼ6-month follow-up; and (4) trial reported in English.
For each trial, we abstracted data for event numbers and annual event rates for nonfatal stroke, nonfatal MI, vascular death, and the composite end point. For event numbers, when Ͼ1 outcome event occurred in 1 patient, only the first event was included (refer to the online-only Data Supplementary).
DALY Formulas
A DALY measures the total amount of optimal life-years lost from a disease process, whether from premature mortality or from incapacity associated with nonfatal conditions. Formally, DALYs are derived from the formula DALYϭYLLϩYLD, where YLL is the years of life lost due to premature death and YLD is the years of healthy life lost due to disability. YLL and YLD are derived by the following formulas 4, 5 :
where K is the age-weighting modulation factor (Kϭ1 or 0); ␤, the parameter from the age-weighting function (␤ϭ0.04 or 0); r, the discount rate (rϭ0.03 or 0), C, a constant (Cϭ0.1658), A, the age of death; L, life expectancy of the general population at age A; DW, the disability weight; A v , age at the vascular event; and L d , the duration of disability (life expectancy after the vascular event at age A v ).
As in the WHO-GBDP, we applied a 3% annual discount rate (rϭ0.03) and age weighting (Kϭ1, ␤ϭ0.04): DALY [3, 1] . The discount rate is the standard health-policy modeling assumption that values a year of healthy life gained in the future less than a year of healthy life gained in the immediate present. The age weighting is another health policy assumption that assigns different values to different years of life: higher in young adult ages than in infancy or at old ages. The values of the age-weighting modulation factor, age-weighting function, constant, and discount rate were derived by the WHO-GBDP from extensive computational modeling.
Life Expectancy Estimation
In this study-level analysis, we did not have available individual patient ages at the time of each end point vascular event. Instead, we used a standardized DALY value for each event type, derived by applying a standard age to all vascular events. In the primary analysis, we set this age to 60. In sensitivity analyses, we varied this assumption to ages 50 and 70. Life expectancies at ages 50, 60, and 70 for MI survivors and for the general population were taken from the Framingham Heart Study (FHS) cohort, as were life expectancies for stroke survivors at ages 60 and 70. 6 The life expectancy of stroke survivors at age 50, not provided in the FHS, was assigned as 11.4 years (3 years shorter than that of MI survivors), based on the FHS observations of the stroke and MI survivors in 50-, 60-, and 70-year-olds. In the FHS, at age 60, the life expectancy for a stroke survivor is 8.9 years (men and women combined); for an MI survivor, 11.2 years; and for the general population, 22.25 years. Accordingly, the age of death was determined as 60 for vascular death, 68.9 for stroke survivors, and 71.2 for MI survivors.
Whereas life expectancy of the general population at age 60 could be taken from the FHS, those of age 68.9 and 71.2 were not provided in the FHS. 6 Because the life expectancies of the FHS general population are quite close to those of the US white population, 7 we used those values: 16.36 years (women and men combined) at age 68 to 69 and 14.62 years at age 71 to 72 (the Figure) .
DWs for Each Vascular Event
We used the DW provided in the WHO-GBDP for the chronic poststroke state of 0.266 and for vascular death of 1.0. 8 For the chronic post-MI state, the WHO-GBDP does not currently provide a unified DW, but one can be derived from the WHO-GBDP-specific DWs for the 2 most common disabling sequelae of MI: chronic heart failure (CHF; DWϭ0.201) and angina pectoris (AP; DWϭ0.124). 8 However, these conditions occur in only a subset of post-MI patients, and even among these, only intermittently. Because the DW of WHO-GBDP was originally derived under the assumption of chronic and persistent symptom and sign, only the disabling days should be counted in deriving a unified DW for the chronic post-MI state. Thus, we used density values that were derived from days of symptom occurrence divided by 365 days. Accordingly, the DW for MI can be derived by the following formula:
where P CHF or P AP is the proportion of MI survivors experiencing CHF or AP, respectively; and Density CHF or Density AP , the number of days per year that these individuals experience CHF or AP, respectively (days divided by 365 days).
From the literature review, we projected P AP as 19.8% and P CHF as 16.9%. 9, 10 For density values, literature review suggested post-MI angina frequencies of 1.2% for daily angina, 3.0% for weekly angina (angina symptom per 2 to 7 days: 81.1 days per year), and 15.6% for angina attacks Ͻ1 day per week for 4 weeks (angina attack per 8 to 28 days: 20.3 days per year), yielding a Density AP of 0.14. For CHF, Density CHF was assigned a value of 1.0 under the assumption of daily symptoms or restriction in daily activities. From these, the DW MI was determined as 0.037.
By applying the values of life expectancies and DWs to the aforementioned formulas, we converted the outcomes of nonfatal stroke, nonfatal MI, and vascular death into DALYs (online-only Data Supplement). To compare the DALY approach with the conventional equal-weighted event analysis, values of the number needed to treat (NNT) for 1 year were derived: NNT event , for preventing 1 event; NNT DALY ϭ100/[DALY saved for 100 patientyears]), for preventing 1 DALY loss (online-only Data Supplement).
Hypothetical Model Trials Analysis
To further illustrate the perspectives afforded by DALY analysis, we also assessed DALYs saved in 6 hypothetical model trials demonstrating 2 different patterns of treatment effect (effective only for stroke prevention or MI prevention) in 3 different populations: population at equal risk for stroke and MI, stroke-prone population, and MI-prone population. For this analysis, we explored the effect of removing age weighting only (DALY [3, 0] ) and removing both age weighting and future discounting (DALY [0,0]) (online-only Data Supplement).
Results
Trials Characteristics
On the basis of expert consensus, we selected 18 trials: 11 secondary stroke prevention trials, 4 secondary prevention trials in coronary heart disease (CHD), and 3 primary prevention trials; 9 trials tested antithrombotics; 3, statins; 3, antihypertensives; 2, estrogens; and 1, surgery ( Table 1; full names of the trials are provided in the in online-only Data Supplement). Table 1 shows that patients in stroke trials had higher stroke rates, and treatments had a greater impact on stroke prevention, whereas patients in CHD trials had higher MI rates and treatments had a greater impact on MI prevention. Based on the magnitude of DALYs saved for the composite end point, the trials were coarsely classified into 4 groups: (1) trials with the greatest DALYs saved of Ϸ20 or more (3 trials); (2) trials saving 5 to 12 DALYs (6 trials); (3) trials with a relatively small DALY gain of Ͻ5 (6 trials); and (4) trials showing DALYs lost (treatment harm, 3 trials).
DALYs Lost for Individual Vascular Events
DALYs Saved by Individual Trials
All stroke and CHD secondary prevention trials nominally reduced nonfatal recurrent events in the initially presenting vascular bed. However, 7 trials (5 stroke trials, 1 CHD trial, and 1 primary prevention trial) showed discrepant treatment effects on other vascular events. Overall, 2 stroke trials and 1 primary prevention trial showed net harm (DALYs lost).
NNT event , NNT DALY , and Comparison of Treatment Effects
NNT values per event and per DALY are shown in Table 4 . Whether a trial treatment was beneficial or harmful was consistent between the DALY and composite-events conventional analyses. However, applying DALYs substantially changed the rank order of treatment effect magnitude compared with the conventional approach: only 8 of 18 trials retained their original ranks (Table I in the online-only Data Supplement). Although the trial with the greatest benefit (anticoagulation for secondary stroke prevention in atrial fibrillation) was consistent between the DALY and conventional approaches, the most harm was observed in anticoagulation for symptomatic intracranial stenosis with the DALY approach and for estrogen for secondary stroke prevention with the conventional approach.
Sensitivity Analysis
Treatment effects were magnified by changing the age at vascular events to 50 and reduced by changing the age at DALY indicates disability-adjusted life-year; YLD, years of healthy life lost due to disability; YLL, years of life lost due to premature death; and MI, myocardial infarction. For DALY ͓3,1͔, both future discounting and age weighting were applied. vascular events to 70, but their ranks remained generally stable whether age 60, 50, or 70 was used (Tables I an II in  the online-only Data Supplement) . Table 5 shows the comparison of hypothetical trials in terms of NNT event and NNT DALY . Compared with the conventional NNT event , NNT DALY more finely discriminated the differences in treatment effects between 6 hypothetical settings. The discriminating power remained robust when age weighting and both age weighting and future discounting were removed.
Hypothetical Trials
Discussion
This study provides standardized DALY values for the most common components of composite end points used in contemporary vascular prevention trials and demonstrates that treatment effects of diverse vascular prevention trials can be presented as a summary patient-centered metric of healthy life-years gained or lost. Formal analysis indicated that the major vascular events routinely assessed in prevention trials are not of equal importance. Rather, compared with a nonfatal MI, a nonfatal stroke causes a 1.48-fold greater loss of disability-adjusted life-years and vascular death, a 2.25-fold greater loss.
A fundamental principle of evidence-based medicine is that assessment of a treatment effect should encompass all of the outcomes that a treatment might alter, in proportion to the degree that they are valued by the patient and society. Consequently, the desirability of weighting components of composite end points in clinical trials has been widely recognized. 11, 12 Several weighting approaches have been suggested, but none to date has captured general allegiance. [12] [13] [14] [15] Most prior weighting algorithms were derived by using informal methods and thin theoretical foundations, thus limiting their acceptance. In contrast, the DALY approach has a strong methodologic framework (person trade-off analyses by internationally representative health providers) and a rich theoretical grounding. It has already achieved wide acceptance as a tool for international health policy analysis and decision-making by the WHO and many health planning authorities. This extensive acceptance in arenas external to clinical trial design gives DALYs credibility and authority for porting into clinical trial planning and analysis.
Another health-adjusted life-year metric, the qualityadjusted life-year (QALY), is also an attractive candidate for weighting outcome end points and already has been used in cost-effectiveness analyses of clinical trial results. Compared with QALYs, DALY analysis has some advantages. QALYs are derived from patients or healthy individuals with a limited experience of diverse disease states and use a wide variety of techniques. 16 As a result, considerable variation across studies occurs in the quality-of-life weights assigned to the same health states. In contrast, DALYs are derived from broadly experienced health professionals in a single, explicit, and broad-based disease comparison framework, resulting in internally coherent weightings for a broad range of conditions.
The functional limitations that vascular events can impose on an individual's remaining life are critically important to patients, families, and society. However, conventional composite end point analysis, counting the number of acute Full names of the trials with references are provided in the in online-only Data Supplement. NNT event indicates the number needed to treat for 1 y to prevent event; NNT DALY , the number needed to treat for 1 y to avert 1 DALY lost. NNT indicates number needed to treat; DALY, disability-adjusted life-year; MI, myocardial infarction; CHD, coronary heart disease; and NR, not reported. NNT indicates number needed to treat; MI, myocardial infarction; and DALY, disability-adjusted life-year. For each hypothetical trial, assumptions of age at onset, event rate, and relative risk reduction by treatment are described in the online-only Data Supplement. For DALY ͓3,0͔, age weighting was removed; for DALY ͓0,0͔, both future discounting and age weighting were removed.
events, provides only a 1-time, snapshot metric that fails to capture the lifelong impact of disease. In contrast, the DALY metric reflects the disparity across the individual vascular events in both event-related premature mortality and reduced human flourishing during an individual's remaining years of life.
The different contributions of disability and premature mortality to the valuations in our study are noteworthy. The DW assigned to the chronic poststroke state was 7 times higher than that for the chronic post-MI state, reflecting the greater frequency and disabling impact of neurologic deficits after stroke than functionally limiting CHF and chronic angina after MI. Consequently, years lost due to disability contributed substantially, 22.1%, to the total DALYs lost due to nonfatal stroke events. In contrast, years lost due to disability only accounted for 5.4% of the loss of optimal health for nonfatal MI, with premature mortality exerting the overwhelming effect.
Weighting the components of composite end points allowed us to derive a single DALY value that summarized for diverse vascular prevention treatments each intervention's net impact on patient health. For treatments that had opposingdirection effects on different end points, a widely recognized challenge to interpretation of composite end points, the DALY resolved and quantified the overall benefit or risk of intervention. Across all treatments, the DALY metric allowed comparisons to be made of the relative degree of benefit delivered by diverse therapies. The greatest benefits were seen in secondary prevention trials, in which enrolled patients are at highest risk for new events; carotid endarterectomy in symptomatic carotid stenosis, anticoagulation for secondary prevention in atrial fibrillation, and clopidogrel added to aspirin in the first year after acute coronary syndrome.
Concurrent validity for the DALY findings is provided by the general consistency of benefit and harm shown with conventional composite end point analysis and DALY analysis. In addition, the DALY analysis permitted a more refined discrimination of interventional efficacy. Across all trials, NTT values to gain 1 healthy life-year were nearly an order of magnitude lower than those needed to avert 1 vascular event. In the hypothetical trial models, DALY analysis demonstrated more clearly than did conventional analysis the variation in degree of benefit obtained when an intervention effective for a specific event is used in patients at high or low risk for that event.
This study has limitations. We analyzed the 3 most common and important end points used in vascular prevention trials. Additional work is needed to derive and apply to clinical trials DALY values for other end points, including unstable angina, transient ischemic attack, hospitalizations for revascularization procedures, and major bleeding episodes.
We performed an analysis of study-level, not individual patient-level, clinical trial data. The most precise application of DALY analysis to clinical trials would use patient-level data, allowing life expectancy calculations to take into account age, sex, country of residency, and other specific characteristics of each patient. 17 However, often only studylevel data are available for analysis. For such settings, a standardized DALY for a prototypical age is useful to convert event counts into DALY values.
An additional limitation of the current analysis is that it focuses on only the first postrandomization vascular event, not all events that may eventually occur. The DALY values that we used only partially capture recurrent events, through reduced life expectancy values, but a more comprehensive depiction of treatment effect would be provided by actual ascertainment and disability weighting of all postrandomization events, not just first events. When patient-level data of subsequent events are available, the DALY metric could directly index the impact of these subsequent events. For example, if a patient had an MI at age 60 and then a stroke at 65 and then die at 70, and the life expectancy of the general population at age 70 is 15.35 years (from the FHS 6 ), the DALY lost for this patient would be the sum of the YLD lost to nonfatal MI for 10 years, YLD to nonfatal stroke for 5 years, and YLL to 15.35 years of premature death (Table III in the online-only Data Supplement).
In trial analyses, we used the same patient ages for MI, stroke, and vascular death events. This approach contrasts with epidemiologic observations showing that MIs tend to occur in younger individuals than do strokes. However, this study measured the burden of stroke and MI in clinical trial populations, and the ages at which MI and stroke occur in a given trial tend to be much closer than in the general population. Life expectancy assumptions were based on FHS data, which had published salient life-expectancy data of poststroke, post-MI, and general populations. The results are therefore most applicable to white populations, but the underlying method can be generalized to other populations whenever salient life-expectancy data are available. Our analyses assumed the same DWs for nonfatal stroke (or MI) across all trials. This assumption does not always hold. For example, strokes experienced by an atrial fibrillation population tend to be more disabling than are strokes in other populations. 18 Data on event severity were generally not available for the trials that we analyzed. When available, incorporating event-severity data will permit more refined DALY estimates of treatment effect. 17, 19 Whereas conventional event-rate analysis of treatment effect is based on direct observations, health-adjusted lifeyear metrics (that is, QALY or DALY) inevitably require several assumptions when determining life expectancies after each vascular event and quantifying health state values. However, equal weighting to different outcomes of different impact on health should be reappraised as reflected in recent debates on the findings of the Carotid Revascularization Endarterectomy versus Stenting Trial. 20 In the Carotid Revascularization Endarterectomy versus Stenting Trial, quality-of-life analyses among survivors at 1 year indicated that stroke had a greater adverse effect on a broad range of health status domains than did MI, consonant with our findings. That the general DALY approach has undergone extensive validation by the WHO and is an accepted foundation for planning global health policies supports its being considered a valuable technique for evaluating treatment effects of vascular prevention trials.
The present study demonstrates that the detailed and nuanced WHO-GBDP DALY framework can be applied to weight composite end point events in cardiovascular trials. The DALY approach, as an integrated, patient-centered outcome metric, complements conventional end point analyses and delineates more clearly the summary impact of a therapy on patient and societal health. 
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SUPPLEMENTAL MATERIAL
Supplemental material 1. Annual event rate abstraction
For each trial, we abstracted data for event numbers and annual event rates for nonfatal stroke, nonfatal MI, vascular death, and composite endpoint. For event numbers, if more than one outcome event occurred in one patient, only the first event was included. If the event number was duplicated across individual events, we first abstracted the numbers of nonfatal stroke, nonfatal MI, and composite endpoint, and then recalculated the numbers of vascular death. However, for the Women's Health Initiative (WHI) trial, the sum of fatal and nonfatal stroke events was less than all stroke events. The life expectancy of 68.9 year-old general population was not provided in the FHS article.
Since the life expectancy of FHS population are quite close to US white population, we employed the life expectancy of this age from US white population life tables.
YLL [3, 1] For nonfatal stroke, the NNT event can be derived from the following calculation: 100/(11.6-3.55)=12.4. NNT DALY can be calculated as follows: 100/(88.55-27.09)=1.6.
Supplemental material 4. Hypothetical model trials assumption and age-weighting and future discounting Hypothetical model trials assumption
In order to further illustrate the perspectives afforded by DALY analysis, we also generated six model trials demonstrating two different patterns of treatment effect in three different populations.
The treatment effect patterns studied were an intervention effective for stroke prevention but ineffective for MI prevention and an intervention effective for MI prevention but ineffective for stroke prevention. The model populations were: 1) patients at equal risk for stroke or MI, 2) strokeprone patients at higher stroke risk than MI, and 3) MI-prone patients at higher MI risk than stroke.
In these six models (two treatment effect patterns crossed with three model populations), we assessed the treatment effect on DALYs for a sample size of 4000 person-years in each arm.
Relative risk reductions were set at 40% on the endpoints for which the treatment was effective and nil for the ineffective endpoints.
For the trials of patients (the average age set to 60) at equal risk for stroke and MI, the annual event rates of control arms were assumed to be 5% for stroke, 5% for MI, and 8% for the composite endpoint. Case fatality rates of 20% were chosen for both stroke and MI, and other vascular death rate was set to 0.5% annually. These assumed control arm event rates were based on data from the systematic review of published stroke prevention trials. 1 It is widely recognized that stroke prevalent age is higher than that of MI. Therefore, for population at unequal risk for stroke and MI, the average age was set at 60 for the stroke-prone population and 50 for the MIprone population. For the stroke-prone population, annual event rates of control arms were assumed to be 5% for stroke and 2.5% for MI. For the MI-prone population, annual event rates of control arms were assumed to be 2.5% for stroke and 5% for MI.
Based on these assumptions, we generated the tabular outcome events, and then derived NNT event and NNT DALY for each hypothetical trials.
Future discounting and age-weighting
The future discounting is a standard health policy modeling assumption that values a year of healthy life lost in the future less than a year of healthy life lost in the immediate present. The ageweighting reflects another assumption that assigns different values to different years of life, higher in young adult ages than in infancy or old ages. As in the WHO-GBDP, we employed an annual 3% of discount rate (r=0.03) and age-weighting (K=1, β=0.04) for the primary DALY analysis (DALY [3, 1] For a patient who has an MI at age 60, and then a stroke at 65, and then die at 70, the DALY lost of this patient would be the sum of the YLD lost to nonfatal MI for 10 years (as he will have post-MI disability until death even after the subsequent stroke), YLD to nonfatal stroke for 5 years, and YLL due to premature death at 70.
The life expectancies for general population at 60, 65 and 70 were assumed to be 22.5, 18.93, and 15.35 years. The life expectancies at 60 and 70 were derived from the data of Framingham study and that at 65 were derived from the extrapolation of these two values. Although, in the main analysis, the DALYs lost for nonfatal stroke and nonfatal MI at 60 were calculated from the assumption of the life expectancy at 60 for stroke survivors as 8.9 years and for MI survivors as 11.2 years based on Framingham study observation, here we assume that patients with nonfatal event without subsequent events will die at 65 or 70 for convenient comparison.
When compared to the DALY lost values for nonfatal MI (5.14) and nonfatal stroke (7.63) at 60 provided in table 2 of the manuscript, those for nonfatal MI at 60 and death at 70 (7.50) and nonfatal stroke at 60 and death at 70 (9.09) in the above table are magnified. This difference is mainly caused by whether future discounting for death event was applied or not. In our main analysis, we were to derive the DALY lost value for the vascular event at 60. In this case, since the death is the future event for patients with nonfatal event, the DALY lost of the future death needs to be discounted (annual discount rate of 3%). 1 However, in this supplemental analysis, as we are to demonstrate how the DALY metric incorporates the subsequent events, we do not apply the future discounting assuming that we prospectively capture the subsequent events.
